[{"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161236", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161242", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161246", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161256", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161274", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161280", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161250", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161260", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161270", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161284", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161216", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161230", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161238", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161240", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161262", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161264", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161266", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161208", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161210", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161218", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161224", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161228", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161254", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161212", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161220", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161226", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161252", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161272", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161276", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161248", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161206", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161214", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161234", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161222", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161278", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161282", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161244", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161258", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161268", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "14950.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161232", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161332", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161342", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161358", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161360", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161374", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161346", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161364", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161368", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161348", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161366", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161370", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161330", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161350", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161356", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161340", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161352", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161372", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161338", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161354", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161334", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161336", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161344", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161362", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "10125.00", "Date_of_Payment": "07/04/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161376", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161286", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161310", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161288", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161290", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161298", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161316", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161306", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161302", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161314", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161322", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161312", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161318", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161304", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161308", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161320", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161296", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161300", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161324", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161292", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7500.00", "Date_of_Payment": "02/07/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161294", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2875.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161200", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2875.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161190", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2875.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161202", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2875.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161204", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2875.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161196", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2875.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161198", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2875.00", "Date_of_Payment": "01/01/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161194", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "750.00", "Date_of_Payment": "03/10/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161328", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "802474", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "750.00", "Date_of_Payment": "03/10/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214161326", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}]